News and Events Recent News Mar 1, 2021 Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia Feb 4, 2021 Arrowhead Pharmaceuticals Reports Fiscal 2021 First Quarter Results Jan 25, 2021 Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia View More » Recent Events Feb 4, 2021 Arrowhead Pharmaceuticals 2021 First Quarter Results Dec 12, 2020 20th Gordon L. Snider Critical Issues Workshop – The Promise of Gene-based Interventions in Alpha-1 Antitrypsin Deficiency Dec 10, 2020 - Dec 12, 2020 National Lipid Association Scientific Sessions 2020 View More »
Mar 1, 2021 Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
Jan 25, 2021 Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Dec 12, 2020 20th Gordon L. Snider Critical Issues Workshop – The Promise of Gene-based Interventions in Alpha-1 Antitrypsin Deficiency